Molecular mechanisms of drug resistance in glioblastoma

60Citations
Citations of this article
168Readers
Mendeley users who have this article in their library.

Abstract

Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, is highly resistant to conventional radiation and chemotherapy, and is not amenable to effective surgical resection. The present review summarizes recent advances in our understanding of the molecular mechanisms of therapeutic resistance of GBM to already known drugs, the molecular characteristics of glioblastoma cells, and the barriers in the brain that underlie drug resistance. We also discuss the progress that has been made in the development of new targeted drugs for glioblastoma, as well as advances in drug delivery across the blood–brain barrier (BBB) and blood–brain tumor barrier (BBTB).

Cite

CITATION STYLE

APA

Dymova, M. A., Kuligina, E. V., & Richter, V. A. (2021, June 2). Molecular mechanisms of drug resistance in glioblastoma. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms22126385

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free